247 related articles for article (PubMed ID: 11956505)
41. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
Dowell JA; Schranz J; Baruch A; Foster G
J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712
[TBL] [Abstract][Full Text] [Related]
42. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
[TBL] [Abstract][Full Text] [Related]
43. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.
Sansone-Parsons A; Krishna G; Martinho M; Kantesaria B; Gelone S; Mant TG
Pharmacotherapy; 2007 Jun; 27(6):825-34. PubMed ID: 17542765
[TBL] [Abstract][Full Text] [Related]
44. Voriconazole-associated myositis.
Shanmugam VK; Matsumoto C; Pien E; Rosen J; Kumar P; Whelton S; Steen V
J Clin Rheumatol; 2009 Oct; 15(7):350-3. PubMed ID: 20009971
[TBL] [Abstract][Full Text] [Related]
45. Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study.
Busnach G; Stragliotto E; Minetti E; Perego A; Brando B; Broggi ML; Civati G
J Nephrol; 1998; 11(2):87-93. PubMed ID: 9589380
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
Liu P; Foster G; LaBadie RR; Gutierrez MJ; Sharma A
J Clin Pharmacol; 2008 Jan; 48(1):73-84. PubMed ID: 18025525
[TBL] [Abstract][Full Text] [Related]
47. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
Mück W; Mai I; Fritsche L; Ochmann K; Rohde G; Unger S; Johne A; Bauer S; Budde K; Roots I; Neumayer HH; Kuhlmann J
Clin Pharmacol Ther; 1999 Mar; 65(3):251-61. PubMed ID: 10096257
[TBL] [Abstract][Full Text] [Related]
48. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.
Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Vyyryläinen H; Laine K
Antimicrob Agents Chemother; 2006 Jun; 50(6):1967-72. PubMed ID: 16723553
[TBL] [Abstract][Full Text] [Related]
49. Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers.
Tarral A; Francheteau P; Guerret M
Pharmacotherapy; 1997; 17(4):791-5. PubMed ID: 9250559
[TBL] [Abstract][Full Text] [Related]
50. Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis.
Chang HH; Lee NY; Ko WC; Lee HC; Yang YH; Wu CJ; Chang CM
Int J Infect Dis; 2010 Apr; 14(4):e348-50. PubMed ID: 19665407
[TBL] [Abstract][Full Text] [Related]
51. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
52. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A; Nieth V; Calandra T; Bille J; Bolay S; Decosterd LA; Buclin T; Majcherczyk PA; Sanglard D; Marchetti O
Antimicrob Agents Chemother; 2007 Jan; 51(1):137-43. PubMed ID: 17088483
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
[TBL] [Abstract][Full Text] [Related]
54. Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.
Tan KK; Trull AK; Uttridge JA; Metcalfe S; Heyes CS; Facey S; Evans DB
Clin Pharmacol Ther; 1995 Apr; 57(4):425-33. PubMed ID: 7712671
[TBL] [Abstract][Full Text] [Related]
55. Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population.
Yang T; Wu XM; Qiu HQ; Fu DH; Hu JD; Li J; Zheng XY; Luo XF; Yuan XH; Chen RL; Chen ZZ
Clin Transplant; 2013; 27(2):255-60. PubMed ID: 23294039
[TBL] [Abstract][Full Text] [Related]
56. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Purkins L; Wood N; Kleinermans D; Love ER
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
[TBL] [Abstract][Full Text] [Related]
57. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole.
Feist A; Lee R; Osborne S; Lane J; Yung G
J Heart Lung Transplant; 2012 Nov; 31(11):1177-81. PubMed ID: 22841559
[TBL] [Abstract][Full Text] [Related]
58. Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial.
Santos P; Lourenço R; Camilo ME; Oliveira AG; Figueira I; Pereira ME; Ferreira B; Carmo JA; Lacerda JM
Clin Nutr; 2001 Feb; 20(1):31-6. PubMed ID: 11161541
[TBL] [Abstract][Full Text] [Related]
59. Interaction between probucol and cyclosporine in renal transplant patients.
Gallego C; Sánchez P; Planells C; Sánchez S; Monte E; Romá E; Sánchez J; Pallardó LM
Ann Pharmacother; 1994; 28(7-8):940-3. PubMed ID: 7949516
[TBL] [Abstract][Full Text] [Related]
60. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
